P38 Mitogen Activated Protein Kinase Is Involved in the Downregulation of Granulocyte CXC Chemokine Receptors 1 and 2 During Human Endotoxemia

Chemokine receptors CXC receptor (CXCR) 1 and 2, and their ligands interleukin (IL)-8 and growth-related oncogene alpha (GRO α), are principal regulators of neutrophil activation and migration. To investigate the role of p38 mitogen activated protein kinase (MAPK) in the regulation of CXCR expression during an inflammatory response in vivo, 24 healthy volunteers received an intravenous injection with lipopolysaccharide (LPS) preceded (−3 hr) by a specific p38 MAPK inhibitor (BIRB 796 BS) at a high dose (600 mg) or a low dose (50 mg) or a placebo. The LPS-induced reduction of neutrophil CXCR 1 and 2 expression, as determined by fluorescence-activated cell sorter analysis, was inhibited in volunteers receiving the high dose of the p38 MAPK inhibitor. The kinase inhibitor also dose dependently diminished the LPS-induced rises in plasma IL-8 and GROα levels. These results indicate a principal role for p38 MAPK in regulating factors essential for neutrophil activation and chemotaxis in vivo..

[1]  A. Chuntharapai,et al.  Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. , 1995, Journal of immunology.

[2]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[3]  A. Matsukawa,et al.  Functional Distinction between CXC Chemokines, Interleukin-8 (IL-8), and Growth Related Oncogene (GRO)α in Neutrophil Infiltration , 2002, Laboratory Investigation.

[4]  M. Su,et al.  The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. , 2001, Blood.

[5]  T. van der Poll,et al.  Expression of the chemokine receptors CXCR1 and CXCR2 on granulocytes in human endotoxemia and tuberculosis: involvement of the p38 mitogen-activated protein kinase pathway. , 2000, The Journal of infectious diseases.

[6]  T. van der Poll,et al.  Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1 , 2002, The Journal of Immunology.

[7]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[8]  D. Kelvin,et al.  Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-alpha-mediated regulation of CXCR1 and CXCR2 chemokine receptor expression. , 1999, Blood.

[9]  K. Steinberg,et al.  Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. , 1999, Journal of immunology.

[10]  Liang Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002 .

[11]  T. van der Poll,et al.  Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. , 1997, Blood.

[12]  John C. Lee,et al.  SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[13]  S. Roman-Roman,et al.  Involvement of Mitogen-Activated Protein Kinase Pathways in Interleukin-8 Production by Human Monocytes and Polymorphonuclear Cells Stimulated with Lipopolysaccharide or Mycoplasma fermentans Membrane Lipoproteins , 1999, Infection and Immunity.

[14]  S. Meddows-Taylor,et al.  Reduced expression of interleukin-8 receptors A and B on polymorphonuclear neutrophils from persons with human immunodeficiency virus type 1 disease and pulmonary tuberculosis. , 1998, The Journal of infectious diseases.

[15]  J. Nick,et al.  Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. , 1996, Journal of immunology.

[16]  T. Williams,et al.  Chemoattractant cross-desensitization of the human neutrophil IL-8 receptor involves receptor internalization and differential receptor subtype regulation. , 1997, Journal of immunology.